IntroductionPalmoplantar involvement in patients with psoriasis can severely impact quality of life and limit work productivity. Topical treatments generally have limited efficacy for moderate‐to‐severe palmoplantar psoriasis. Systemic treatments such as methotrexate, acitretin, tumour necrosis factor alpha (TNF‐α) inhibitors (etanercept, adalimumab and infliximab) and interleukin 17A or 12/23 inhibitors (secukinumab and ustekinumab) have been reported to be efficacious. However, their efficacy in palmoplantar psoriasis is usually lower than when they are used for psoriasis vulgaris. Only 30–40% of patients with moderate‐to‐severe palmoplantar psoriasis achieve a Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0/1 after 12–16 weeks of treatment with biologics. There is a need for the development of novel treatments for palmoplantar psoriasis.Apremilast is an oral phosphodiesterase inhibitor, that is approved for the treatment of psoriasis and psoriatic arthritis. A post hoc analysis of palmoplantar data from three phase 2 and 3 studies conducted in patients with moderate‐to‐severe psoriasis vulgaris suggested that apremilast could be effective for the treatment of psoriasis involving palms and soles. However, this analysis included all patients presenting at least a moderate severity based on physician global assessment of palmoplantar disease regardless of the surface area involved with palmoplantar psoriasis at baseline. This study evaluates the efficacy
Journal of the European Academy of Dermatology & Venereology – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud